Literature DB >> 3566246

In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia burgdorferi, to four antimicrobial agents.

R C Johnson, C Kodner, M Russell.   

Abstract

The antimicrobial susceptibility of Borrelia burgdorferi isolated from human spinal fluid was determined in vitro and in vivo. A broth dilution technique was used to determine the MBCs of four antimicrobial agents. The Lyme disease spirochete was most susceptible to ceftriaxone (MBC, 0.04 microgram/ml) and erythromycin (MBC, 0.05 microgram/ml), then tetracycline (MBC, 0.8 microgram/ml), and finally penicillin G (MBC, 6.4 micrograms/ml). Syrian hamsters were used to determine the 50% curative doses (CD50s) of the four antimicrobial agents. Ceftriaxone and tetracycline had the highest activities, with CD50s of 24.0 and 28.7 mg/kg [corrected], respectively. Both erythromycin and penicillin G possessed low activities. The CD50 of erythromycin was 235.3 mg/kg [corrected], and the CD50 of penicillin G was greater than 197.5 mg/kg [corrected].

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3566246      PMCID: PMC174684          DOI: 10.1128/AAC.31.2.164

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Erythema chronicum migrans--a tickborne spirochetosis.

Authors:  W Burgdorfer; A G Barbour; S F Hayes; O Péter; A Aeschlimann
Journal:  Acta Trop       Date:  1983-03       Impact factor: 3.112

2.  Treatment of the early manifestations of Lyme disease.

Authors:  A C Steere; G J Hutchinson; D W Rahn; L H Sigal; J E Craft; E T DeSanna; S E Malawista
Journal:  Ann Intern Med       Date:  1983-07       Impact factor: 25.391

3.  Natural Distribution of the Ixodes dammini spirochete.

Authors:  E M Bosler; J L Coleman; J L Benach; D A Massey; J P Hanrahan; W Burgdorfer; A G Barbour
Journal:  Science       Date:  1983-04-15       Impact factor: 47.728

4.  Spirochetes isolated from the blood of two patients with Lyme disease.

Authors:  J L Benach; E M Bosler; J P Hanrahan; J L Coleman; G S Habicht; T F Bast; D J Cameron; J L Ziegler; A G Barbour; W Burgdorfer; R Edelman; R A Kaslow
Journal:  N Engl J Med       Date:  1983-03-31       Impact factor: 91.245

5.  The spirochetal etiology of Lyme disease.

Authors:  A C Steere; R L Grodzicki; A N Kornblatt; J E Craft; A G Barbour; W Burgdorfer; G P Schmid; E Johnson; S E Malawista
Journal:  N Engl J Med       Date:  1983-03-31       Impact factor: 91.245

6.  Lyme disease-a tick-borne spirochetosis?

Authors:  W Burgdorfer; A G Barbour; S F Hayes; J L Benach; E Grunwaldt; J P Davis
Journal:  Science       Date:  1982-06-18       Impact factor: 47.728

7.  Erythema chronicum migrans and Lyme arthritis. The enlarging clinical spectrum.

Authors:  A C Steere; S E Malawista; J A Hardin; S Ruddy; W Askenase; W A Andiman
Journal:  Ann Intern Med       Date:  1977-06       Impact factor: 25.391

8.  Comparison of the activities of ceftriaxone and penicillin G against experimentally induced syphilis in rabbits.

Authors:  R C Johnson; R F Bey; S J Wolgamot
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

9.  Spirochetes in Ixodes dammini and mammals from Connecticut.

Authors:  J F Anderson; L A Magnarelli; W Burgdorfer; A G Barbour
Journal:  Am J Trop Med Hyg       Date:  1983-07       Impact factor: 2.345

10.  Neurologic abnormalities of Lyme disease: successful treatment with high-dose intravenous penicillin.

Authors:  A C Steere; A R Pachner; S E Malawista
Journal:  Ann Intern Med       Date:  1983-12       Impact factor: 25.391

View more
  47 in total

Review 1.  Spirochaetal lipoproteins and pathogenesis.

Authors:  D A Haake
Journal:  Microbiology       Date:  2000-07       Impact factor: 2.777

2.  Culture of the entire mouse to determine whether cultivable Borrelia burgdorferi persists in infected mice treated with a five-day course of Ceftriaxone.

Authors:  Charles S Pavia; Gary P Wormser
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

3.  Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents.

Authors:  R C Johnson; C B Kodner; P J Jurkovich; J J Collins
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 4.  Lyme disease in paediatrics.

Authors:  B Cryan; D J Wright
Journal:  Arch Dis Child       Date:  1991-11       Impact factor: 3.791

5.  Efficacy of short-course ceftriaxone therapy for Borrelia burgdorferi infection in C3H mice.

Authors:  Charles Pavia; Mario A Inchiosa; Gary P Wormser
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

Review 6.  Antibiotic treatment of animals infected with Borrelia burgdorferi.

Authors:  Gary P Wormser; Ira Schwartz
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

7.  Concentrations of doxycycline and penicillin G in sera and cerebrospinal fluid of patients treated for neuroborreliosis.

Authors:  M Karlsson; S Hammers; I Nilsson-Ehle; A S Malmborg; B Wretlind
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

8.  Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi.

Authors:  V Preac-Mursic; B Wilske; G Schierz; E Süss; B Gross
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-07       Impact factor: 3.267

9.  Efficacy of clarithromycin for treatment of experimental Lyme disease in vivo.

Authors:  J Alder; M Mitten; K Jarvis; P Gupta; J Clement
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

10.  Persistent atrioventricular block in Lyme borreliosis.

Authors:  W Mayer; F X Kleber; B Wilske; V Preac-Mursic; W Maciejewski; H Sigl; E Holzer; W Doering
Journal:  Klin Wochenschr       Date:  1990-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.